The ryanodine receptor type 1 gene variants in African American men with exertional rhabdomyolysis and malignant hyperthermia susceptibility

Clinical Genetics

Volumn 76, Issue 6, 2009, Pages 564-568

  Sambuughin, N ^a   Capacchione, J ^a   Blokhin, A ^a   Bayarsaikhan, M ^a   Bina, S ^a   Muldoon, S ^a  

^a Uniformed Services University of the Health Sciences and the Walter Reed National Military Medical Center   (United States)

Author keywords

African Americans; Exertional rhabdomyolysis; Malignant hyperthermia; Mutation; RYR1

Indexed keywords

RYANODINE RECEPTOR 1;

ADULT; AFRICAN AMERICAN; AMINO ACID SEQUENCE; ARTICLE; CAFFEINE HALOTHANE CONTRACTURE TEST; CLINICAL ARTICLE; CLINICAL ASSESSMENT TOOL; GENE IDENTIFICATION; GENETIC CONSERVATION; GENETIC POLYMORPHISM; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MALE; MALIGNANT HYPERTHERMIA; PRIORITY JOURNAL; RHABDOMYOLYSIS;

ADULT; AFRICAN AMERICANS; CASE-CONTROL STUDIES; DNA MUTATIONAL ANALYSIS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MUSCLE CONTRACTION; MUTATION; PHENOTYPE; PHYSICAL EXERTION; RHABDOMYOLYSIS; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; YOUNG ADULT;

EID: 70749157377     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01251.x     Document Type: Article

References (22)

1. O'Connor F, Deuster P, Goldman L, Ausiello DA. Rhabdomyolysis. Cecil medicine 2008, 798-802. In:, eds., 23rd edn, Philadelphia, Saunders Elsevier
2. Warren J, Blumbergs P, Thompson P. Rhabdomyolysis: a review. Muscle Nerve 2002, 25:332-347.
3. Poels P, Joosten E, Sengers R. In vitro contraction test for malignant hyperthermia in patients with unexplained recurrent rhabdomyolysis. J Neurol Sci 1991, 105:67-72.
4. Ogletree J, Antognini J, Gronert G. Postexercise muscle cramping associated with positive malignant hyperthermia contracture testing. Am J Sports Med 1996, 24:49-51.
5. Kochling A, Wappler F, Winkler G, Schulte am Esch J. Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth Intensive Care 1998, 26:315-318.
6. Wappler F, Fiege M, Steinfath M. Evidence for susceptibility to malignant hyperthermia in patients with exercise-induced rhabdomyolysis. Anesthesiology 2001, 94:95-100.
7. Davis M, Brown R, Dickson A. Malignant hyperthermia associated with exercise-induced rhabdomyolysis or congenital abnormalities and a novel RYR1 mutation in New Zealand and Australian pedigrees. Br J Anaesth 2002, 88:508-515.
8. Nelson TE. A pharmacogenetic disease of Ca++ regulating proteins. Curr Mol Medicine 2002, 2:347-369.
9. McCarthy TV, Heffron JA, Mackrill J, Wehrens XTH, Marks AR. Molecular and clinical genetics of RYR1 disorders. Ryanodine receptors: structure, function and dysfunction in clinical disease 2005, 219-227. In:, eds., New York, Springer
10. Robinson RL, Carpenter D, Shaw M, Halsall J, Hopkins P. Mutations in RYR1 in malignant hyperthermia and central core disease. Hum Mutat 2006, 27:977-989.
11. Ibarra C, Wu S, Murayama K. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology 2006, 104:1146-1154.
12. Sambuughin N, Holley H, Muldoon S. Screening of the ryanodine receptor type 1 coding region for sequence variants associated with malignant hyperthermia susceptibility in the North American population. Anesthesiology 2005, 102:515-521.
13. Sei Y, Sambuughin N, Davis EJ. Malignant hyperthermia in North America: screening the three hotspots in the type I ryanodine receptor gene. Anesthesiology 2004, 101:824-830.
14. Hugo JM, Ungerer MJ, Erasmus FR, du Toit PW, Muller FO. Malignant hyperthermia in a black child: a case report. S Afr Med J 1978, 53:807-810.
15. Lompard TP, Couper JL. Desflurane a trigger of malignant hyperthermia in a black adolescent. S Afr Med J 1988, 73:726-729.
16. Lane JE, Brooks AG, Logan MS, Newman WWH, Castresana MR. An unusual case of malignant hyperthermia during desflurane anesthesia in an African American patient. Anesth Analg 2000, 91:1032-1034.
17. Larach MG. Standardization of the caffeine halothane muscle contracture test. North American Malignant Hyperthermia Group. Anesth Analg 1989, 69:511-515.
18. Soledad L, Vukcevic M, Singer M. Increasing the number of diagnostic mutations in malignant hyperthermia. Hum Mutat 2009, 30:590-598.
19. Monnier N, Krivosic-Horber R, Payen JF. Presence of two different genetic traits in malignant hyperthermia susceptibility. Anesthesiology 2002, 97:1067-1074.
20. Zhou H, Yamaguchi N, Xu L. Characterization of recessive RYR1 mutations in core myopathies. Hum Mol Genet 2006, 15:2791-2803.
21. Brown RL, Pollock AN, Couchman KG. A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigree. Hum Mol Genet 2000, 9:1515-1524.
22. Robinson RL, Anesteder MJ, Brancadoro V. Recent advances in the diagnosis of malignant hyperthermia susceptibility: How confident can we be of genetic testing?. Eur J Hum Genet 2003, 11:342-348.